Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest BRAF Stories

2012-05-21 05:26:29

(Ivanhoe Newswire) — Some say the number of cases is growing at an epidemic rate! In fact, melanoma is the fastest growing cancer in the U.S. Now, a new study shows the drug, dabrafenib, has been shown to have the most activity of any systematic treatment to date against secondary melanoma tumours in the brain. A phase 1 trial shows the new drug causes substantial shrinking of metastatic tumours in patients. Dabrafenib blocks the activity of the cancer-causing mutated form of the...

2012-05-18 23:51:29

3-pronged study reveals high response rate in other advanced melanoma patients and activity in multiple cancers An experimental drug targeting a common mutation in melanoma successfully shrank tumors that spread to the brain in nine out of 10 patients in part of an international phase I clinical trial report in the May 18 issue of The Lancet. The drug dabrafenib, which targets the Val600 BRAF mutation that is active in half of melanoma cases, also cut the size of tumors in 25 of 36...

2012-05-17 02:25:47

SAN DIEGO and JERUSALEM, May 17, 2012 /PRNewswire/ -- Ambit Biosciences and Teva Pharmaceutical Industries Limited (NASDAQ: TEVA) ("Teva") today announced the clearance of an Investigational New Drug application (IND) with the U.S. Food and Drug Administration (FDA) for CEP-32496, a novel BRAF (V600E) kinase inhibitor. The IND filing was based upon promising therapeutic potential for this agent, as evidenced by data revealed in recent publications in the Journal of Medicinal Chemistry and...

2012-05-10 23:00:47

The human body does a great job of generating new cells to replace dead ones but it is not perfect. Cells need to communicate with or signal to each other to decide when to generate new cells. Communication or signaling errors in cells lead to uncontrolled cell growth and are the basis of many cancers. At The University of Texas Health Science Center at Houston (UTHealth) Medical School, scientists have made a key discovery in cell signaling that is relevant to the fight against melanoma...

2012-04-29 15:10:12

Genetic profiling helps find answers to melanoma drug resistance At Moffitt Cancer Center, patients with stage III and IV unresectable melanoma are now routinely genetically profiled for several gene mutations, including the BRAF gene, a known driver oncogene for melanoma. Research has shown that mutations in the BRAF gene determine sensitivity or resistance to a class of drugs that are BRAF inhibitors. "We have found that a large number of patients with melanoma who have the BRAF gene...

2012-04-02 12:53:53

A second mutation found in the tumors of patients with BRAF-mutated metastatic melanoma does not contribute to resistance to BRAF inhibitor drugs, a finding that runs counter to what scientists expected to be true. The study by researchers at UCLA's Jonsson Comprehensive Cancer Center found that patients with the mutations in both the MEK1 and BRAF genes respond as well to the inhibitors as patients with the BRAF mutation alone. Another surprising finding is that the MEK1 and BRAF...

2012-03-17 00:12:34

Oral BRAF inhibitor can extend survival to 16 months for some patients An international team of researchers from the United States and Australia, including researchers at Moffitt Cancer Center in Tampa, Fla., have found that the oral BRAF inhibitor vemurafenib (PLX4032) when tested in a phase II clinical trial offered a high rate of response in patients with previously treated metastatic melanoma and who had the BRAF mutation. More than 50 percent of the patients in the trial had positive,...

2012-03-09 06:50:00

(Ivanhoe Newswire) — Cancer has various ways of evading drugs used by oncologists to try and eliminate the disease. Now, new research is showing how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene. Scientists examined the part of the melanoma genome that encodes proteins (called the exome) and discovered that in some patients with BRAF-mutated metastatic melanoma, the mutated BRAF gene that forms the cancer becomes amplified as the...

2012-03-06 22:51:59

Cancer is tough to kill and has many ways of evading the drugs used by oncologists to try and eliminate it. Now, researchers at UCLA's Jonsson Comprehensive Cancer Center have uncovered how an advanced form of melanoma gets around an inhibitor, Zelboraf, which targets the mutated BRAF gene. By examining the part of the melanoma genome that encodes proteins, called the exome, Jonsson Cancer Center scientists discovered that in some patients with BRAF-mutated metastatic melanoma, the...

Vemurafenib Doubles Survival Of Metastatic Melanoma Patients
2012-03-03 04:33:40

A report published this week in the New England Journal of Medicine shows that the 50 percent of metastatic melanoma patients with a specific genetic mutation benefit from the drug Vemurafenib — increasing median survival from about 6 months to 15.9 months. In patients who responded, the drug stopped cancer progression for a median 6.7 months. “For melanoma patients with a BRAF V600 mutation, this drug is a breakthrough. Not a cure, but a major breakthrough,” says Karl...